Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
2
67%
Ph not_applicable
1
33%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Completed(1)

Detailed Status

Completed1
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
N/A1 (33.3%)

Trials by Status

completed133%
recruiting133%
active_not_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
recruitingnot_applicable

Reach Through Equitable Implementation in Utah

NCT06881069
active_not_recruitingphase_1

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

NCT01586403
completedphase_1

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

NCT02088203

Clinical Trials (3)

Showing 3 of 3 trials
NCT06881069Not Applicable

Reach Through Equitable Implementation in Utah

Recruiting
NCT01586403Phase 1

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Active Not Recruiting
NCT02088203Phase 1

Evaluation of Soy-protein Russian Tarragon (Artemisia Dracunculus L.)

Completed

All 3 trials loaded

Drug Details

Intervention Type
DIETARY SUPPLEMENT
Total Trials
3